Could blocking granzymes protect nerves in MS?

Credibility

Interest

Share:2 min read

Key Takeaway

Proteins called granzymes, especially Granzyme B, can worsen brain and nerve inflammation and damage, and blocking them outside cells may help protect people with MS.

What They Found

Granzymes are immune proteins once thought to only kill infected cells, but they also act outside cells to break down support structures and turn on inflammation, which can harm nerves. Granzyme B (GzmB) is best studied and can both damage nerve cells from inside and, when outside cells, cut the “glue” around cells, trigger inflammation signals, and weaken barriers that protect the brain and retina. Granzyme A (GzmA) can chop up tau, a protein that helps nerve cells keep their shape, and may destabilize neurons and astrocytes (support cells), making tissues more fragile. Granzyme K (GzmK) can change how microglia (brain immune cells) behave and can turn on parts of the immune system that amplify inflammation, sometimes helping and sometimes hurting depending on the situation. Granzyme H (GzmH) is less understood but may also play a role in nerve injury; researchers are exploring drugs that block these granzymes outside cells, with the most promise so far for blocking GzmB.

Who Should Care and Why

People with MS and their caregivers should care because MS involves harmful inflammation and nerve damage, and granzymes appear to be one of the drivers of that inflammation. Think of granzymes like workers who normally remove dangerous cells, but when they go rogue they start breaking the building’s walls and wiring, making symptoms worse. Neurologists and MS care teams may consider future treatments that block granzymes outside cells to reduce ongoing damage, similar to putting up protective scaffolding so repairs don’t cause more harm. Patients with active inflammation, progressive symptoms, or eye problems (like retinal damage) may especially benefit from therapies that target granzymes. Caregivers can use this information to ask doctors about research trials or new drugs aimed at calming harmful immune activity in the brain.

Important Considerations

Most findings come from lab and animal studies, so we don’t yet know how well granzyme-blocking treatments will work and how safe they will be in people with MS. Currently, only GzmB has good evidence and promising drug leads; selective blockers for GzmA, GzmK, and GzmH are not yet available. This means these ideas are promising but still experimental, so talk with your care team before expecting or seeking granzyme-targeted treatments.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Progression Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Acta neuropathologica often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News